A $7.3 million operating loss turned into a $0.5 million profit at Neuronetics.
Neuronetics (STIM) reported Q3 2026 revenue of $42.0M, up 12.5% YoY, with Greenbrook revenue rising 20.1% to $26.2M. Adjusted EBITDA turned positive at $1.9M, and net loss narrowed to $1.6M. The company submitted a 510(k) application for accelerated TMS and partnered with Wave Neuro for PTSD treatment. Full-year revenue guidance remains $160M-$164M.
How this was made
The 30-second read
Why it matters
While the profit reversal is positive, the data were already disclosed in the August filing, limiting fresh trading impetus.
Market read
Recap of already‑public earnings; modest short‑term price effect possible, but no new catalyst.
What to watch
Pending FDA 510(k) for accelerated TMS and PTSD partnership could be more material than the current earnings numbers.
Background
Neuronetics (NASDAQ:STIM) released its Q3 2026 results, showing a $0.5 M profit versus a $1.6 M loss a year earlier, with revenue growth and new partnership announcements.
Ticker impact
Quarterly report shows operating loss turned to profit and improved revenue, but numbers were already public from the August filing.
potential modest upside as investors note the profit swing, though limited by prior disclosure
The figures were released 85 days earlier; the article adds no new data, so any price move would be limited to short-term re‑reaction.
Market effects
TMS and mental‑health device sector sees no material shift; the report reinforces existing outlook.
U.S. market impact minimal; no broader regional effect.
Limited global relevance beyond investors tracking niche med‑tech stocks.
Counterpoint
The profit swing may be overstated if future guidance remains unchanged; investors could remain cautious.
Key entities
- companyNeuronetics, Inc.
Provider of NeuroStar TMS technology and Greenbrook clinic network.
- companyWave Neuro
Partner for PTSD treatment integration.
